State of Biomedical Innovation – Global Leaders share ideas at Brookings

On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference.


Dr. Jeffrey Trent, TGen

Dr. Jeffrey Trent, TGen

The Brookings Institute  shared that “the goal of this conference was to assess U.S. biomedical innovation and discuss policy solutions that ensure the nation remains a world leader. This year, the conference featured an update to last year’s discussion of the drivers of innovation and how best to track them through use of comprehensive metrics. In addition, the conference specifically focused on novel sources and applications of big data in innovation, with senior-level thought leaders from government, academia, industry, patient advocacy, and clinical care present to share their views and recommendations.”The Innovation in Action panel, moderated by Dr. Mark McClellan, Director, Health Care Innovation and Value Initiative at Brookings included Dr. Jeffrey Trent, President and Research Director for the Translational Genomics Research Institute (TGen) and former Scientific Director of the National Human Genome Research Institute.   Dr. Trent shared how TGen’s ongoing work in translating genomics research translates into clinical benefit. TGen is one of a very few centers who are using the entire human genome in clinical trials in order to diagnose or make treatment decisions for an individual patient (precision medicine).

IBM Watson Brookings

Dr. Martin Kohn, Watson Research Center, IBM

Martin Kohn, Chief Medical Scientist, Care Delivery Systems at the Watson Research Center, IBM shared insights on how Watson delivers insights from vast quantities and provides decision support to researchers and physicians can make better decisions.

Gabriel Eichler, General Manager, Client Services & Strategic Initiatives at PatientsLikeMe shared how their model is helping to benefit patients who are voluntarily providing genomic data to shared databases that can provide  treatment insights while Dalvir Gill, Chief Executive Officer at TransCelerate BioPharma Inc. focused on how cross industry collaboration in the clinical trials space are helping to reduce costs and improve results by addressing systematic issues.
The conference proceedings are available for play back at:  The panel can be viewed at the 1:58:54 mark.

# # #

About the Brookings Institution
The Brookings Institution is a nonprofit public policy organization based in Washington, DC. Our mission is to conduct high-quality, independent research and, based on that research, to provide innovative, practical recommendations that advance three broad goals: strengthen American democracy; foster the economic and social welfare, security and opportunity of all Americans; and secure a more open, safe, prosperous and cooperative international system. Brookings is proud to be consistently ranked as the most influential, most quoted and most trusted think tank. More information:


Posted in AZBio News, Health, Members and tagged , , , , , .